Form 4: RVMD CFO Sells Shares Under Pre-Arranged 10b5-1 Plan
Insider Transaction Report
Revolution Medicines CFO Jack Anders exercised options and sold 10,000 shares of common stock for $98.00 per share under a pre-arranged 10b5-1 trading plan.
Summary
- Chief Financial Officer Jack Anders of Revolution Medicines, Inc. (RVMD) executed transactions on January 7, 2026.
- Exercised stock options to acquire 10,000 shares of common stock at an exercise price of $42.45 per share.
- Sold 10,000 shares of common stock at a price of $98.00 per share.
- Both transactions were conducted pursuant to a Rule 10b5-1 trading plan adopted on December 16, 2024.
- Following these transactions, Anders beneficially owns 108,065 shares of common stock, which includes 42,338 restricted stock units.
- Anders also beneficially owns 15,900 stock options after the reported transactions.
Sentiment
Score: 5
Explanation: Neutral. The filing reports a routine insider transaction under a pre-arranged plan, which is neither inherently positive nor negative for the company's operational outlook or fundamental value.
Positives
- The CFO realized a significant profit from the option exercise and subsequent sale, with shares sold at $98.00 against an exercise price of $42.45.
- Transactions were conducted under a pre-arranged 10b5-1 trading plan, indicating a planned disposition rather than a reaction to recent events or material non-public information.
Negatives
- An insider, the Chief Financial Officer, sold 10,000 shares of common stock.
Future Outlook
This filing does not contain any forward-looking statements or guidance regarding the company's future outlook.
Industry Context
This insider transaction report does not provide specific industry context or relate to broader industry trends or competitors.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Insider Trading Plan | CFO Jack Anders executed transactions under a Rule 10b5-1 trading plan adopted on December 16, 2024. This plan allows insiders to pre-arrange sales of company stock to avoid accusations of trading on material non-public information. | December 16, 2024 | Enhances transparency and reduces potential for insider trading concerns by scheduling stock sales in advance, demonstrating adherence to corporate governance best practices. |
Stakeholder Impact
- Shareholders: May view the insider sale with slight caution, but the pre-arranged nature under a 10b5-1 plan mitigates concerns about the timing or motivation of the sale.
Key Dates
| Date | Description |
|---|---|
| December 16, 2024 | Date the 10b5-1 trading plan was adopted by the Reporting Person. |
| March 4, 2025 | Date the stock option became exercisable. |
| January 7, 2026 | Date of the stock option exercise and common stock sale transactions. |
| January 9, 2026 | Date the Form 4 was signed by the Reporting Person. |
| March 3, 2031 | Expiration date of the stock option. |
Recommendation
holdThe filing details a routine insider transaction by the CFO under a pre-arranged 10b5-1 plan. While an insider sale occurred, its planned nature and relatively modest size do not provide sufficient new information to alter an investment thesis for Revolution Medicines, Inc. Investors should consider broader company fundamentals and market conditions rather than this single transaction.
Keywords
Revolution Medicines, RVMD, Jack Anders, CFO, Insider Trading, Form 4, Stock Option Exercise, Share Sale, 10b5-1 Plan, Biotechnology, Pharmaceuticals
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.